High Bioavailability Resveratrol Delivery System: A Novel Nutritional Strategy for the Prevention and Alleviation of Rheumatoid Arthritis

TL;DR

A new delivery system for resveratrol improves its absorption and effectiveness in preventing rheumatoid arthritis in rats.

Contribution

A novel solid dispersion system using Eudragit E PO significantly enhances resveratrol bioavailability and anti-arthritic effects.

Findings

The RSV-E PO solid dispersion achieved over 80% resveratrol release in vitro, a 13-fold increase compared to raw resveratrol.

Oral administration of the compound doubled resveratrol bioavailability in rats compared to unformulated resveratrol.

The compound reduced pro-inflammatory cytokines and oxidative stress markers while increasing antioxidant enzyme activity in an arthritis model.

Abstract

This study aimed to develop an oral solid dispersion nutrient delivery system of resveratrol (RSV) and Eudragit E PO (E PO) for the prevention of rheumatoid arthritis. The RSV‐E PO solid dispersion, prepared by the solvent method at a drug—polymer ratio of 1:7 (w/w), turned resveratrol into an amorphous state, as proved by SEM, DSC, XRD, and FTIR. Over 80% of resveratrol was released in vitro, a 13‐fold increase compared to raw resveratrol. In male Sprague—Dawley rats, its oral administration (20 mg·kg−1) doubled bioavailability versus unformulated resveratrol. Evaluated in an adjuvant‐induced arthritis (AIA) model, the compound demonstrated significant anti‐arthritic effects. These protective effects were primarily mediated through the modulation of key inflammatory and oxidative stress pathways, as evidenced by a marked reduction in pro‐inflammatory cytokines (IL‐6, TNF‐α, IL‐1β) and malondialdehyde (MDA) levels, coupled with an increase in the anti‐inflammatory cytokine IL‐10 and the antioxidant enzyme superoxide dismutase (SOD). Also, its safety was confirmed by stable AST, ALT, CREA, and BUN levels. In summary, the RSV‐E PO solid dispersion, with better dissolution and bioavailability, serves as an effective oral nutrient delivery system for RSV.

This study developed a high bioavailability resveratrol delivery system for rheumatoid arthritis prevention using solid dispersion. Its oral administration (20 mg·kg−1) doubled bioavailability versus unformulated resveratrol, and the serum biomarkers related to liver and kidney function did not increase, indicating that the preparation has good safety.

Figures